Quiz Pre test APLAR LUPUS SHORT COURSE Session 1

Pre-test questionnaire, which is intended to assess participants’ current knowledge and help us better tailor the session. The pre-test is not part of final assessment but is mandatory to attempt before the final test.

PRE-TEST AND POST-TEST (ONLY INTERNAL USE IN THIS COURSE)

Please fill your information

Name

Country

Organization

Job Title

Would you like to become APLAR Academy member (conmplementary) to receive further information on Academy activities?

Yes - I would like to become APLAR Academy member

No - I don't want to

Which statement is correct about DORIS remission:

A. cSLEDAI <4, PhGA < 1, normal Anti-dsDNA, low Complement, prednisolone < 5mg/d, on HCQ and/or stable immunosuppressants

B. cSLEDAI =0, PhGA < 0.5, increased Anti-dsDNA, low Complement, prednisolone < 5 mg/d, on HCQ and/or stable immunosuppressants

C. cSLEDAI <4, PhGA < 0.5, normal Anti-dsDNA, normal Complement, prednisolone < 5 mg/d, on HCQ and/or stable immunosuppressants

D. cSLEDAI =0, PhGA < 1, increased Anti-dsDNA, low Complement, prednisolone < 5 mg/d, on HCQ and/or stable immunosuppressants

E. cSLEDAI <4, PhGA < 0.5, normal Anti-dsDNA, normal Complement, prednisolone < 7.5 mg/d, on HCQ and/or stable immunosuppressants

None

Which vaccination is better to be avoided in active SLE patients on immunosuppressant?

A. Hepatitis B vaccine

B. Measles Mumps Rubella (MMR)

C. Pneumococcal vaccine

D. Human Papilloma Virus (HPV) Vaccine

E. Recombinant Zoster vaccine (RZV)

None

Which is not included in Definition of Lupus Low Disease Activity Status (LLDAS):

A. SLE Disease Activity Index (SLEDAI)-2K ≤4, with no activity in major organ systems

B. No new lupus disease activity compared with the previous assessment

C. SELENA-SLEDAI physician global assessment (scale 0-3) ≤0.5

D. Prednisolone dose ≤7.5 mg daily

E. Well tolerated immunosuppressive drugs and approved biological agents.

None

Which of the following statements is incorrect regarding active infection and SLE flare,:

A. During active infection CRP is elevated but no change in Anti ds-DNA

B. During SLE flare procalcitonin is elevated but leukocytes are decreased

C. During SLE flare Anti ds-DNA is elevated but leukocytes are decreased

D. During active infection procalcitonin is elevated but complement is decreased

E. During SLE flare ESR is elevated but CRP is not changed or minimally elevated

None

Which of the following is the most appropriate initial treatment for musculoskeletal manifestations of SLE?

a. Hydroxychloroquine

b. Methotrexate

c. Prednisolone

d. Leflunomide

None

Musculoskeletal symptoms, such as arthralgia, myalgia, and arthritis, are common manifestations in SLE patients. What is the approximate prevalence of these musculoskeletal features in established SLE?

a. 33%

b. 50%

c. 75%

d. Close to 100%

None

A 32-year-old woman with multiple joint pains and swelling, hair loss, malar rashes, oral ulcers, and extreme fatigue of 3 months duration is being evaluated in a clinic. Investigations reveal a high titre of ANA, low C3, low titre dsDNA, and high titre Rheumatoid factor and anti-CCP antibodies. What type of joint pathology would you expect in this patient?

a. Arthralgia

b. Erosive arthritis

c. Jaccoud’s arthropathy

d. Non-erosive arthritis

None

The primary immunologic pathomechanism in SLE is:

A. Isolated T-cell dysfunction

B. Loss of immune tolerance with autoantibody production

C. Primary complement deficiency

D. Neutrophil-driven inflammation

None

Which statement/s is/are true of Easy-BILAG?

A. Consists of 4 levels of disease activity similar to BILAG-2004

B. First page captures items which require aggressive or urgent management

C. Second page captures infrequent and rare SLE manifestations

D. All of the above

None

10.

Which requirement is common to both LLDAS and DORIS:

A. Absence of disease activity

B. Damage (SDI) accrual <1

C. Prednisone dose <5mg/day

D. Stable immunosuppressive drugs and biologics

None

1 out of 5

You have reached the end of the quiz.

To review your answer from the previous page, click the previous button.

If you are ready to submit your quiz, click the submit button.

Thank you.

Social Media

Subscribe

ALL RIGHTS RESERVED © 2023 | APLAR.ORG